Strong mid-stage data defy doubts following rival Pfizer’s spin off.
GSK ends long-running work targeting NY-ESO-1, and that’s bad news for Adaptimmune as well as Lyell.
The developer has now struck two rich deals for the antibiotics space, a field that infrequently sees big sums change hands.
Pfizer’s Irak-4 inhibitor PF-06650833 definitely, definitely doesn’t work in hidradenitis suppurativa, but there’s at least partly better news for Priovant.
Blank cheque companies might have disappointed, but options are limited right now for private developers in need of big bucks.
Growing interest in protein degradation helps explain why Bayer had to pay $1.5bn to corner the private group.
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.